The DILI‐sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation
暂无分享,去创建一个
[1] S. Siler,et al. Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials , 2017, Clinical pharmacology and therapeutics.
[2] P. Watkins,et al. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors , 2016, Toxicological sciences : an official journal of the Society of Toxicology.
[3] Munir Pirmohamed,et al. The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.
[4] Hugh A. Barton,et al. Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development , 2016 .
[5] John M. Burke,et al. Quantitative systems toxicology , 2017, Current opinion in toxicology.
[6] D. Day,et al. Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters , 1975, The Journal of pathology.
[7] Y. Yang,et al. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury , 2016, CPT: pharmacometrics & systems pharmacology.
[8] C. Battista,et al. Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters , 2017, Clinical pharmacology and therapeutics.
[9] Paul B Watkins,et al. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. , 2014, Biopharmaceutics & drug disposition.
[10] P. Watkins,et al. Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH) , 2011, Drug safety.
[11] P. Watkins,et al. The transformation in biomarker detection and management of drug‐induced liver injury , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[12] Leslie Z Benet,et al. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[13] P. Watkins,et al. Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa) , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[14] A. D. Rodrigues,et al. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective , 2018, Clinical pharmacology and therapeutics.
[15] J. Cai,et al. Toll-like receptors and radiation protection. , 2018, European review for medical and pharmacological sciences.
[16] D. Abernethy,et al. Application of Systems Pharmacology to Explore Mechanisms of Hepatotoxicity , 2014, Clinical pharmacology and therapeutics.
[17] Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.
[18] A. Rosenberg,et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[19] Jerome T. Mettetal,et al. Using Quantitative Systems Toxicology to Investigate Observed Species Differences in CKA-Mediated Hepatotoxicity , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[20] P B Watkins,et al. Drug Safety Sciences and the Bottleneck in Drug Development , 2011, Clinical pharmacology and therapeutics.
[21] Y. Dragan,et al. Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[22] H. Barnhart,et al. Death and liver transplantation within 2 years of onset of drug‐induced liver injury , 2017, Hepatology.
[23] Melvin E. Andersen,et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[24] N. Kaplowitz,et al. Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis , 2017, International journal of molecular sciences.
[25] M. Mosedale,et al. Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management , 2017, Clinical pharmacology and therapeutics.
[26] P. Watkins,et al. Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling , 2018, Clinical and translational science.
[27] P. Watkins,et al. Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses , 2017, Gene regulation and systems biology.
[28] P. Watkins,et al. A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial , 2014, CPT: pharmacometrics & systems pharmacology.
[29] P. Watkins,et al. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI , 2014, CPT: pharmacometrics & systems pharmacology.
[30] The publishing and patenting strategies of successful university spinoffs in the biopharmaceutical industry. , 2017, Drug discovery today.
[31] Paul B Watkins,et al. Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone Hepatotoxicity , 2014, Clinical pharmacology and therapeutics.
[32] Paul B Watkins,et al. Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. , 2014, Toxicology letters.
[33] R. Roth,et al. Neutrophil- and Glutathione-Mediated Hepatotoxicity of α-Naphthylisothiocyanate , 1997 .
[34] K. He,et al. Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury. , 2015, Chemical research in toxicology.
[35] Hugh A. Barton,et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..
[36] K. Brouwer,et al. Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[37] Melvin E. Andersen,et al. An Analysis of N-Acetylcysteine Treatment for Acetaminophen Overdose Using a Systems Model of Drug-Induced Liver Injury , 2012, Journal of Pharmacology and Experimental Therapeutics.
[38] Paul B Watkins,et al. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials , 2018, Experimental biology and medicine.
[39] Paul B Watkins,et al. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. , 2017, Drug metabolism and pharmacokinetics.